Review outlines anaesthetic planning for dogs with MMVD: full analysis

A new narrative review in the Journal of Small Animal Practice focuses on a familiar but often uneasy clinical scenario: how to assess and manage anaesthetic risk in dogs with myxomatous mitral valve disease. Rather than treating MMVD as a single anaesthetic category, the authors frame care as a spectrum, arguing that risk assessment should reflect disease stage, cardiovascular compensation, procedure type, and the monitoring and intervention capacity of the practice. That message lands in a large patient population, because MMVD is widely recognized as the most common heart disease in dogs. (pubmed.ncbi.nlm.nih.gov)

The backdrop is a field that already has strong cardiology guidance, but less consolidated anaesthesia-specific direction. The 2019 ACVIM consensus statement revised recommendations for diagnosis and treatment of canine MMVD and emphasized that management before the onset of heart failure had changed substantially from the 2009 guidance. It also formalized stage-based thinking that now shapes how clinicians discuss prognosis, monitoring, and treatment, particularly in dogs with preclinical disease and cardiomegaly. (pubmed.ncbi.nlm.nih.gov)

That matters because many dogs with MMVD present for procedures that aren’t primarily cardiac. In practice, these patients may need dental work, imaging, mass removal, or other interventions where delaying anaesthesia also carries consequences. The review’s core contribution appears to be its attempt to bridge that gap with a pragmatic framework: not simply asking whether a dog has MMVD, but asking how advanced the disease is, whether the dog is compensated, what drugs it is receiving, how urgent the procedure is, and what level of intraoperative and postoperative support is available. Based on the abstract provided, the authors also highlight a limitation of the ASA physical status system in this setting: it correlates with mortality, but remains subjective and may not capture the nuance of preclinical MMVD. (pubmed.ncbi.nlm.nih.gov)

The wider MMVD literature supports the need for that nuance. The EPIC trial showed that in dogs with preclinical MMVD and cardiomegaly, pimobendan delayed the onset of congestive heart failure, reinforcing that “preclinical” does not mean clinically trivial. Subsequent work from the EPIC dataset tracked temporal changes in radiographic and clinical variables as dogs progressed, underscoring how dynamic these patients can be over time. In other words, anaesthetic planning for a dog with stable stage B1 disease is not the same as planning for a dog with stage B2 enlargement or a history of congestive heart failure. (pubmed.ncbi.nlm.nih.gov)

Direct outside commentary on this specific review was limited in the sources available, but the broader specialty conversation has been moving toward earlier staging, better phenotyping, and more individualized management of MMVD. Recent studies have looked at prognostic markers, focused cardiac ultrasound training, and newer interventional or surgical approaches, all pointing to a field that is becoming more stratified and data-driven. That context makes a “spectrum of care” anaesthesia review timely, because it mirrors how cardiologists and general practitioners already think about MMVD outside the operating room. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical value is less about a single new protocol and more about clinical framing. Dogs with MMVD are common in first-opinion practice, and many can safely undergo needed procedures if teams match anaesthetic intensity, monitoring, and perioperative planning to disease stage and current stability. The review may help clinics formalize when a workup can stay in-house, when referral is warranted, how to think about medication continuation, and how to communicate risk to pet parents in a way that is specific rather than alarmist. It also reinforces that cardiac disease should be part of procedural planning from the start, not an afterthought discovered on the day of anaesthesia. (pubmed.ncbi.nlm.nih.gov)

Another important point is resource sensitivity. The “spectrum of care” framing suggests the authors are trying to make the guidance usable across different practice settings, not just specialty hospitals. That could be especially helpful for general practitioners managing older small-breed dogs with murmurs, where the decision is often not between “perfect” and “unsafe,” but between proceeding thoughtfully, postponing for more staging, or referring for advanced support. This is where a review can influence workflows even without changing formal guidelines. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step will be whether this review is picked up in CE, practice protocols, and future consensus discussions, particularly around standardized pre-anaesthetic checklists or stage-linked recommendations for dogs with MMVD. (pubmed.ncbi.nlm.nih.gov)